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Abstract
Introduction. Multivalvular heart disease has either a congenital or an acquired aetiology (e.g. rheumatic fever, athe-
rosclerosis, calcification of the valves, remodelling and dilatation of ventricles). The basis of valvular degeneration is 
failure of endothelial tissue. The consequence of a long-standing heart defect is progressive heart failure (HF). The aim 
of this study was to underline the fact that HF and atrial fibrillation are frequently related to combined valvular disease.
Material and methods. The study involved documentation of 109 patients with a compound heart defect treated from 
2006 to 2016. Other factors which were considered in the statistical calculation were: HF classified according to the 
New York Heart Association scale, presence of cardiac infarction, diabetes, macrophage activation syndrome, obesity, 
circulatory arrest, dyspnoea, chest pain, fatigability, unconsciousness, dizziness and performed cardioversion.
Results. HF was diagnosed in 65 cases (59.5%). 55 patients with diagnosed HF who were simultaneously suffering from 
mixed valvular heart disease had no other diseases of the cardiovascular system. There was no correlation between 
HF and heart infarct or coronary arterial disease. We found no dependency between the grade of HF (defined as NYHA 
classes II, III and IV) and diabetes mellitus etc.
Conclusions. The risk for the development of these diseases in the research group was much higher than in the general 
population. It is essential to pay special attention to the concomitance of HF, atrial fibrillation and valvular diseases.
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Introduction
Mixed valvular heart disease refers to coexisting valvular 
stenosis and regurgitation. Combined valvular disease is 
the name given to describe any disease process involving 
two or more of the four heart valves. In practice, combined 
heart disease is called multivalvular disease (MVD). One 
of the most frequent of the acquired aetiologies of MVD 
is rheumatic fever.
Moreover, there is steadily rising occurrence of de-
generative disease associated with atherosclerosis (a rise 
associated with rising life expectancy), and this is yet an-
other reason for valvular damage occurrence. Aortic valve 
degeneration and mitral annular calcification are common 
changes associated with the ageing process. Remodelling 
and dilatation of the right and left ventricles (triggered by 
myocardial infarction or myocarditis) are significant fac-
tors of secondary or functional valvular regurgitation [1].
Broadly speaking, we can divide the factors influencing 
the degeneration of heart valves into: 1) genetic factors 
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decide whether echocardiography is required. Patients at 
high risk of HF must receive immediate echocardiography 
[7].
HF is classified according to the severity of the symp-
toms. The most commonly used classification system is 
that of the New York Heart Association (NYHA). The classi-
fications are set out in Table 1 [8]. In advanced HF (NYHA 
class IV), roughly half of patients die within 12 months [9]. 
The most frequent reason for heart failure with reduced 
ejection fraction (HFrEF) is ischaemic heart disease. Other 
causes include uncontrolled hypertension, valvular heart 
disease and cardiomyopathies. Heart failure with correct 
ejection fraction is usually caused by hypertension with left 
ventricle hypertrophy or ischaemic heart disease, diabe-
tes, hypertrophic or restrictive cardiomyopathy, constrictive 
pericarditis. HF risk factors include female sex, advanced 
age, and being overweight [9].
The aim of this study was to underline the importance 
of paying special attention to the fact that HF and atrial fi-
brillation (AF) are frequently related to MVD.
Materials and methods
Our study is based on the documentation of 109 cases 
recorded in the Clinic of Cardiology. The research involved 
68 female and 39 male patients with a compound heart 
defect treated in the Clinic of Cardiology in Lublin from 2006 
to 2016. Inclusion criteria were age 18 years or over, and 
a compound heart defect (i.e. defect of two or more valves). 
Exclusion criteria were: age under 18; defect of one valve; 
absence of any heart defect; or a case not recorded in the 
Clinic of Cardiology in Lublin.
Other factors which were considered in the statistical 
calculation were HF classified in the NYHA scale, presence 
of cardiac infarction, diabetes, macrophage activation 
syndrome (MAS), obesity, circulatory arrest, dyspnoea, 
chest pain, fatigability, unconsciousness, dizziness and 
performed cardioversion.
Statistical analysis
The occurrence of these diseases in the examined group 
was characterised in terms of numbers and percentages. 
In order to prove the relevance of two nominal variables 
(homozygous familial hypercholesterolemia); 2) clinical 
factors (arterial hypertension, diabetes mellitus, smoking, 
obesity); 3) biochemical factors (higher levels of lipoprotein 
A, total cholesterol, low-density lipoprotein (LDL)-cholesterol, 
lower levels of high-density lipoprotein (HDL)-cholesterol, 
higher concentrations of calcium, creatinine and C-reactive 
protein in blood tests); and 4) demographic factors (age, 
sex).
The basis of valvular degeneration is failure of endo-
thelial tissue. As a result of endothelium discontinuation, 
lipids, lipoproteins and proteins are deposited. Infiltrates 
consisting of inflammatory cells are formed (macrophages, 
T-lymphocytes, foam cells), fibrosis and calcification. Fur-
thermore, new cardiovascular risk factors are not without 
significance. These include a high level of C-reactive pro-
tein, fibrinogen, interleukin 6, lipoprotein A, homocyste-
ine, matrix metalloproteinase, and lipoprotein-associated 
phospholipase A2 (Lp-PLA2). Intima-media thickness and 
resting heart rate > 70–80/min may also affect endothe-
lial tissue. These factors contribute to both atherosclero-
sis and degenerative lesions. The sole method of treating 
aortic stenosis is surgery [2, 3].
The consequence of a long-standing heart defect is 
progressive heart failure (HF). At present, the most fre-
quent HF aetiologies in Poland (and Europe in general) 
are coronary arterial disease and hypertension [4]. HF 
is a condition in which the heart cannot keep up with tis-
sue’s demands for oxygen. That demand can be fulfilled 
only by increased filling pressure [5]. We can divide HF 
into right-sided or right ventricular (RV) heart failure and 
left-sided or left ventricular (LV) HF. The following are the 
symptoms of RV heart failure: swelling of feet, ankles or 
sacral region in recumbent patients, nocturia, pleural ef-
fusion, ascites, hepatomegaly (and also liver atrophy when 
the HF is of long standing), high jugular venous pressure, 
and Kussmaul’s sign. The signs of LV HF are: dyspnoea, 
cough and symptoms during auscultation of lungs (crack-
les or rattling) [6].
When symptoms develop suddenly, a chest X-ray must 
be taken followed by echocardiography. When symptoms 
develop slowly, meaning that ambulatory care is possible, 
we can make an electrocardiography (ECG) or check the 
natriuretic peptide level, and with reference to these results 
Table 1. New York Heart Association (NYHA) functional classifications
NYHA class Characteristic
I Average physical activity does not cause undue symptoms (breathlessness, palpitations or fatigue)
II Ordinary physical activity results in undue symptoms (breathlessness, palpitations or fatigue)
III Marked limitation of physical activity. Symptoms do not occur at rest, but less than ordinary physical  
activity results in undue breathlessness, palpitations or fatigue
IV Patient is unable to carry on physical activity without discomfort. Symptoms can occur at rest. Physical  
activity results in increased discomfort
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only from multivalvular heart disease, or in the group of 
patients with both multivalvular heart disease and HF: 
see Table 3.
It is clear that 55 patients with diagnosed HF who were 
simultaneously suffering from mixed valvular heart disease 
had no other diseases of the cardiovascular system. The-
se clinical results are statistically significant (p < 0.05, 
Cramér’s V = 0.653).
Discussion
Chronic heart failure occurs in 1–2% of the adult popula-
tion in developed countries. In addition, more than 10% of 
people over the age of 70 suffer from chronic heart failure 
[10]. In Poland it is reported that 600,000–700,000 pa-
tients have HF. Moreover, every fifth person will develop HF 
during their lifespan [11].
The results of our paper show that patients with com-
bined valvular disease have HF more frequently than other 
patients (60.55% of the examined patients had HF). In Eu-
rope, the most frequent cause of HF in patients under 75 is 
myocardial infarction. In patients over 75 it is hypertension. 
Other risk factors are myocardial hypertrophy, myocardial 
cell loss and fibrosis, cardiomyopathies, myocarditis, val-
vular diseases and arrhythmias [5]. HF usually caries an 
adverse prognosis, and the five-year survival rate is worse 
than in the case of many neoplasms [11]. The diagnosis 
algorithm for HF is shown in Figure 1 [12]. The treatment 
is based on angiotensin-converting-enzyme inhibitors or 
(in the case of side effects like a cough) on angiotensin 
receptor blockers. Furthermore, β-blockers and diuretics 
such as spironolactone can be applied. The next group of 
medications are cardiac glycosides and vasodilators. In 
late stage HF, catecholamines are used (dobutamine and 
a new inotrope called levosimendan). In the case of coex-
isting respiratory insufficiency, assisted respiration should 
be applied (patients with saturation < 90% must receive 
oxygen therapy, and continuous positive airway pressure 
(CPAP), bilevel positive airway pressure (BiPAP) ventilation 
or mechanical ventilation are permissible). Patients with 
saturation > 90% do not require oxygen therapy [7, 12, 13].
The other most frequent medical condition in the ex-
amined group was AF which accounted for 56.88% of the 
group. As a comparison, in the USA, AF has been diagnosed 
in 0.7% of the whole population [14, 15], and just over 2% of 
the adult population [16]. We would like to emphasise that 
in this research AF was usually the only disease (except 
for valvular disease) which can lead to HF. Patients with 
other diseases are classified in Table 2. Atrial fibrillation 
frequently occurs with valvular heart disease. Statistical-
ly, in a case of severe mitral valve stenosis, the frequen-
cy of coexisting AF stands at 10% in patients under the 
age of 30, and is higher in the case of older patients. AF 
is diagnosed frequently in conjunction with an advanced 
the χ2 test was used. Statistical evaluation of results was 
carried out using STATISTICA v.20 (StatSoft, Poland).
Results
All patients with multivalvular heart disease were treated at 
the Department of Cardiology from 2006 to 2016. Women 
accounted for 62.4% of the whole group (N = 68), with men 
the remaining 35.8% (N = 39). The average age of the group 
was 68.8 years (the oldest patient was 96, the youngest 
41, standard deviation was 13.7092).
In the group of patients with combined valvular dis-
ease, the following accompanying diseases were reported: 
14 suffered from myocardial infarction (MI); there were nine 
ST-elevation myocardial infarction (STEMI) cases (8.3% of 
all patients) and five non-ST-elevation myocardial infarction 
(NSTEMI) cases (4.6% of all cases). More than one MI oc-
curred in one patient. 37 patients suffered from coronary 
artery disease (CAD) (33.9% of all cases). One patient had 
type 1 diabetes and 20 patients had type 2 diabetes. In one 
case, steroid-induced diabetes was noted and one patient 
had impaired fasting glucose (IFG). 66 patients were diag-
nosed with HF classified as class II, III or IV on the NYHA 
scale. The most common valvular defect was mitral regur-
gitation (MR): 10 cases of grade 1+, 53 cases of grade 2+, 
30 cases of grade 3+, and five cases of grade 4+. 85 pa-
tients had tricuspid regurgitation (TR): 21 cases of grade 
1+, 36 cases of grade 2+, 28 cases of grade 3+, and one 
case of grade 4+. 84 patients were diagnosed with aor-
tic regurgitation (AR): 24 cases of grade 1+, 41 cases of 
grade 2+, 14 cases of grade 3+, and five cases of grade 
4+. 49 patients had aortic valve stenosis. Mitral valve ste-
nosis was diagnosed in 21 cases. 14 patients had pulmo-
nary valve regurgitation (PR): 11 cases of grade 1+, two 
cases of grade 2+, and one case of grade 3+.
In the group of 109 patients with multivalvular heart 
disease, HF was diagnosed in 65 cases (59.5%). One in 
four patients suffered from Grade II HF according to the 
NYHA scale (N = 28, 25.7%), one in five from grade III HF 
(N = 21, 19.3%), and one in six from Grade IV HF (N = 16, 
14.7%). Myocardial infarction occurred in 15 cases (13.8%), 
while coronary artery disease occurred in 37 cases (33.9%). 
Arterial hypertension (AH) was diagnosed in 62 patients 
(56.9%), AF also in 62 cases (56.9%), and pulmonary hy-
pertension in 16 cases (14.7%). Every sixth patient had an 
implanted pacemaker (N = 17, 15.6%), and one patient had 
an implantable cardioverter-defibrillator (ICD): see Table 1.
Precise characteristics of the study group are set out 
in Table 2.
There were no statistically significant differences in the 
frequency of occurrence of intercurrent illnesses such as 
myocardial infarction, coronary artery disease, diabetes 
mellitus, pulmonary hypertension, arterial hypertension, 
aortic aneurysm and AF in the group of patients suffering 
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stage of aortic valve diseases or with significant haemo-
dynamic tricuspid valve insufficiency [16].
HF can cause AF, and AF can lead to HF. According to 
the EURObservational Research Programme: The Heart 
Failure (ESC-HF) Pilot Survey Pilot Survey of patients with 
diagnosed HF, 40% of them had AF as well. On the other 
hand, symptoms of HF (NYHA classes II–IV) occur in about 
30% of patients with AF [16].
The treatment of AF is multistage. In short-term 
treatment (less than 48 h), electrolyte disorders should 
be corrected. The treatment of the second phase is 
cardioversion (pharmacological cardioversion with 
propafenone or electrical cardioversion with amioda-
rone). To prevent AF recurrence, some therapeutic drugs 
can be used. Dronedarone, flecainide, propafenone, 
or sotalol can be administered to patients with correct 
left ventricular function and without myocardial hyper-
trophy. In the case of patients with stable coronary ar-
tery disease and with no HF, dronedarone can be used. 
Patients with diagnosed HF can receive amiodarone. 
Moreover, anticoagulants should be considered (espe-
cially when the AF continues for more than 48 hours): 
vitamin K antagonists (VKA), or new oral anticoagulants 
(NOACs). If the prognosis of sinus rhythm maintenance 
Table 2. Characteristics of study group
Frequency Percentage [%]
Heart failure No 44 40.4
Yes 65 59.6




Myocardial infarction (MI) No 94 86.2
Yes 15 13.8
Type of myocardial infarction
not applicable 94 86.2
STEMI 9 8.3
NSTEMI 5 4.6
> 1 MI 1 0.9
Coronary artery disease No 72 66.1
Yes 37 33.9
Diabetes mellitus (DM) No 86 78.9
Type 1 1 0.9
Type 2 20 18.3
Steroid-induced diabetes 1 0.9
Impaired fasting glucose 
(IFG) 1 0.9
Pulmonary hypertension 16 14.7
Arterial hypertension 62 56.9
Aortic aneurysm 8 7.3
MAS 4 3.7
Lipid disorders 6 5.5
Cardiac arrest 5 4.6
Rheumatic heart disease 1 0.9
Atrial fibrillation 62 56.9
Pacemaker 17 15.6
Cardioverter-defibrillator 1 0.9
HYHA — New York Heart Association; STEMI — ST-elevation myocardial infarction; NSTEMI — non-ST-elevation myocardial infarction, MI — myocardial infarction; MAS — macrophage activation syndrome
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of these diseases in our research group was significantly 
higher than in the general population.
The study carried out in this paper does not prove any 
correlation between other diseases of the cardiovascular 
system and mixed valvular heart disease. Consequently, 
it is essential to pay special attention to concomitant HF, 
AF and valvular diseases.
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is poor, percutaneous and surgical ablation should be 
considered. In the event of chronic AF, or when the po-
tential risk of therapy is higher than its benefits, correct 
ventricular rhythm should be maintained (heart rate c. 
80–100/min). Beta-blockers, verapamil, diltiazem or di-
goxin can be used in the treatment [7, 17].
Conclusions
We wish to stress that HF and AF are frequently related to 
combined valvular disease. The risk for the development 
Table 3. Intercurrent illnesses in group of patients with only multivalvular heart disease and in group of patients with multivalvular heart 
disease and simultaneous heart failure
Only multivalvular  
heart disease 
(N = 44)
Multivalvular heart  
disease + heart failure 
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Streszczenie
Wstęp. Wielozastawkowa wada serca może mieć etiologię wrodzoną lub nabytą (np. gorączka reumatyczna, miażdżyca 
tętnic, zwapnienia zastawek, przebudowa i poszerzenie komór serca). Podstawą degeneracji zastawek jest wada endo-
telium. Długotrwająca wada zastawek prowadzi do postępującej niewydolności serca (HF). Celem pracy było zwrócenie 
uwagi na fakt, że HF i migotanie przedsionków są związane z wielozastawkową wadą serca.
Materiały i metody. Niniejsza praca stanowi analizę dokumentacji 109 pacjentów leczonych z powodu złożonej wady 
zastawkowej w latach 2006–2016. W obliczeniach statystycznych wzięto pod uwagę również inne czynniki, takie jak: 
HF sklasyfikowaną według skali New York Heart Association (NYHA), przebyty zawał serca, cukrzycę, współwystępowanie 
zespołu aktywacji makrofagów (MAS), otyłość, przebyte zatrzymanie krążenia, duszność, ból w klatce piersiowej, 
męczliwość, zawroty głowy, przeprowadzony zabieg kardiowersji.
Wyniki. Niewydolność serca nie korelowała z wadami zastawek (p > 0,05) ani z zawrotami głowy (p = 0,9). Co więcej, 
nie dowiedzionno korelacji między HF a zawałem serca lub chorobą wieńcową. Autorzy nie wykazali korelacji między II 
a IV stopniem HF według klasyfikacji NYHA a cukrzycą.
Wnioski. Ryzyko wystąpienia tych schorzeń w badanej grupie było dużo wyższe niż w populacji ogólnej. Ważnym jest więc 
zwracanie szczególnej uwagi na możliwe współwystępowanie HF, migotania przedsionków i złożonej wady zastawkowej 
serca.
Słowa kluczowe: złożona wada zastawkowa, niewydolność serca, migotanie przedsionków
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Figure 1. Diagnostic algorithm for diagnosis of HF of non-acute onset (according to [4]); HF — heart failure; CAD — coronary artery disease; 
ECG — electrocardiography; NT-proBNP — N-terminal pro-B-type natriuretic peptide; BNP — B-type natriuretic peptide; Normal — normal 
ventricular and atrial volume and function
Patient with suspected HF (non-acute onset)
Assessment of HF probability
Clinical history
History of CAD, history of arterial hypertension, exposure to cardiotoxic drugs, use of diuretics, 
orthopnoea, paroxysmal nocturnal dyspnoea
Physical examination




NT-proBNP ≥ 125 pg/mL












If HF confirmed (based on all available data) determine 
aetiology and start appropriate treatment
No
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